POS1144 EFFECTIVENESS OF BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS OF A MULTICENTER SPANISH COHORT

Background Belimumab (BLM) is a recombinant human IgG-1λ monoclonal antibody that inhibits B-cell activating factor. It approved for the treatment of systemic lupus erythematosus (SLE). effective in reducing disease activity, flares, damage prevention and also as steroid-sparing agent. A treat to target (T2T) approach care SLE patients important terms improving short long-term outcomes. Objectives To evaluate belimumab effectiveness from Spanish multicenter registry. Methods longitudinal retrospective cohort including treated with 18 rheumatology departments. Demographic, clinical serological data were collected at baseline, 6, 12 last visit available. Changes SLEDAI-2K; LLDAS DORIS 2021 states global response according physician criteria compared between visits, well changes glucocorticoids used. T-test was used numerical variables Fisher’s test categorical variables. Results 324 included: 295 (91%) females mean (±SD) age 42.4 (±12.9) years. Mean follow-up 3,8 (±2.7) years time BLM 2.7 (±2.4) At SLEDAI-2K 10.4 (±5.25), 68.2% had elevated anti-double-stranded DNA (anti-dsDNA) antibodies 69.8% complement consumption. initiated concomitant other DMARD 67.9% (n=220) patients. reduction score 5.0 (± 5.1), 6.1 ( ± 5.5) 7.13 5.3) points months visit, respectively (p<0.05 all comparisons). Rates achievement LLDAS, criteria, significantly increased baseline months, (Table 1). Anti-dsDNA inflammatory markers (ESR, CRP), decreased visit. Complements over follow up but without statistical significance. total 107 (45,9%) discontinued GC. 6 58.9% (n=155) reduced dose GC respect 72.8% (n=131) did it SD) prednisone reduce visits: 12.3 12.16); 7.42 5.36); 5.8 (±4.42) 4.7 (±3.7) mg/day respectively. Median (IQR) SDI end observation period not change visit: 0 (0-1) (0-1), (p=0.97). Neither observed percentage beginning period: 47.5% (n=152) presented and, 45.6% (n=99). Table 1. Clinical dose. Disease activity or number (%); n=324 Baseline Last SLEDAI reduction; (±SD ) 10 5.25) 5.1) * (1.9%) 137(45.8%) 145 (62%) 177 (73.1%) 72 (24%) 85 (36.3%) 127 (52.5%) Response 212 (65.4%) 185 (57.1%) 165 (50.9%) Number swollen joints; 3.3 (±3.6) 1.2 (±2.8) 0.69 (±1.95) 0.55 (±1.82) Prednisone (mg/day); 12.16) 7.4 5,36) 4,42) 4.75 (±3.74) SLEDAI: Systemic Lupus Erythematosus Activity Index . cSLEDAI: SLEDAI; LLDAS: Low State DORIS: Definition remission *p<0.05 Figure therapeutic targets attained by Belimumab. Discontinued 45 74 130 Ongoing 279 250 194 Conclusion Real-world confirm efficacy real world, medium-term. Add-on therapy leads high rates continue increasing time. has an sparing effect prevents organ accrual. All these shows useful achieve goals T2T strategy. REFERENCES: NIL. Acknowledgements: Disclosure Interests None Declared.